Background: Malignant tumor is still one of the important diseases worldwide, cytotoxic
CD8+ T lymphocytes (CTLs) play an important role in killing tumor cells.
Objective: To enhance the immune response of our previously identified HLA-A2-restricted CTL
epitopes, we designed a multiepitope YL66.
Method: The fusion protein GST-YL66 and DNA vaccine pcDNA3.1(+)-YL66 were used to induce
CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*02+
healthy donors and
and in HLA-A2.1/Kb
transgenic(Tg) mice. and the activity of induced CTLs were tested by IFN-γ
relesde ELISPOT assay and LDH cytotoxicity assay.
Results: GST-YL66 induced CTL could lysis tumor cells and release IFN-γ both in vitro
and in vivo
and pcDNA3.1(+)-YL66 could also induce significant CTL response in vivo.
Conclusion: The designed fusion multiepitope YL66 could be used as a vaccine against patients with
tumors expressing COX-2 and/or MAGE-4.